BCL7B was expected to show potential as a biomarker for prognosis and immunotherapy analysis due to a correlation found between BCL7B expression and immune cell infiltration in sarcoma [48], and interestingly, the correlation was found to be reversed in certain cancer types [49]. This evidence concerns the gene BCL7B and cancer.